Trial Profile

A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 May 2025 According to a Tiziana Life Sciences media release, this trial is expected to reach top line data read out at the end of 2025.
23 Apr 2025 According to a Tiziana Life Sciences media release, dosing has commenced at the fourth clinical site The University of Massachusetts (UMass).
02 Apr 2025 According to a Tiziana Life Sciences media release, company announced dosing has commenced at Johns Hopkins University (JHU) Autoimmunity Center of Excellence, and company expects the blinded portion of the trial to be completed by the end of 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com